Vaccinations for infants, toddlers, and preschoolers opened within the U.S. in June after months of delay. Solely about 6% of children ages 6 months by means of 4 years had gotten at the very least one dose of a COVID-19 vaccine by mid-August, based on the American Academy of Pediatrics.
Well being authorities approved tot-sized vaccine doses made by Pfizer and its accomplice BioNTech based mostly on a examine displaying they had been protected and produced excessive ranges of virus-fighting antibodies. However there was solely preliminary knowledge on how that translated into effectiveness in opposition to symptomatic COVID-19.
There have been 21 COVID-19 instances among the many 351 tots who received dummy photographs—in comparison with simply 13 among the many 794 children given three vaccine doses.
The kid instances primarily had been attributable to the BA.2 Omicron model that was circulating on the time. Right now, one other Omicron relative, BA.5, is inflicting most COVID-19 instances within the U.S. and far of the world.
In older youngsters and adults, the COVID-19 vaccines have been used lengthy sufficient to show that they continue to be strongly protecting in opposition to extreme illness and loss of life even because the coronavirus mutates—whereas early safety in opposition to an infection wanes. Nonetheless, scientists observe that preliminary effectiveness fee as further proof of vaccine efficiency—and to search for indicators of how they initially maintain up in opposition to new mutants.
Pfizer this week asked U.S. regulators to authorize modified vaccine doses that higher match the latest Omicron variants for individuals 12 and older as boosters this fall. The corporate mentioned it is also growing up to date photographs for teenagers beneath 12.
Extra Should-Learn Tales From TIME